Historical Valuation
Sellas Life Sciences Group Inc (SLS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.52. The fair price of Sellas Life Sciences Group Inc (SLS) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：3.41
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Sellas Life Sciences Group Inc (SLS) has a current Price-to-Book (P/B) ratio of 11.92. Compared to its 3-year average P/B ratio of 6.58 , the current P/B ratio is approximately 81.30% higher. Relative to its 5-year average P/B ratio of 6.25, the current P/B ratio is about 90.65% higher. Sellas Life Sciences Group Inc (SLS) has a Forward Free Cash Flow (FCF) yield of approximately -4.94%. Compared to its 3-year average FCF yield of -49.35%, the current FCF yield is approximately -89.99% lower. Relative to its 5-year average FCF yield of -39.76% , the current FCF yield is about -87.57% lower.
P/B
Median3y
6.58
Median5y
6.25
FCF Yield
Median3y
-49.35
Median5y
-39.76
Competitors Valuation Multiple
AI Analysis for SLS
The average P/S ratio for SLS competitors is 45.52, providing a benchmark for relative valuation. Sellas Life Sciences Group Inc Corp (SLS.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SLS
1Y
3Y
5Y
Market capitalization of SLS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SLS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SLS currently overvalued or undervalued?
Sellas Life Sciences Group Inc (SLS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.52. The fair price of Sellas Life Sciences Group Inc (SLS) is between to according to relative valuation methord.
What is Sellas Life Sciences Group Inc (SLS) fair value?
SLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sellas Life Sciences Group Inc (SLS) is between to according to relative valuation methord.
How does SLS's valuation metrics compare to the industry average?
The average P/S ratio for SLS's competitors is 45.52, providing a benchmark for relative valuation. Sellas Life Sciences Group Inc Corp (SLS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Sellas Life Sciences Group Inc (SLS) as of Jan 10 2026?
As of Jan 10 2026, Sellas Life Sciences Group Inc (SLS) has a P/B ratio of 11.92. This indicates that the market values SLS at 11.92 times its book value.
What is the current FCF Yield for Sellas Life Sciences Group Inc (SLS) as of Jan 10 2026?
As of Jan 10 2026, Sellas Life Sciences Group Inc (SLS) has a FCF Yield of -4.94%. This means that for every dollar of Sellas Life Sciences Group Inc’s market capitalization, the company generates -4.94 cents in free cash flow.
What is the current Forward P/E ratio for Sellas Life Sciences Group Inc (SLS) as of Jan 10 2026?
As of Jan 10 2026, Sellas Life Sciences Group Inc (SLS) has a Forward P/E ratio of -16.11. This means the market is willing to pay $-16.11 for every dollar of Sellas Life Sciences Group Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Sellas Life Sciences Group Inc (SLS) as of Jan 10 2026?
As of Jan 10 2026, Sellas Life Sciences Group Inc (SLS) has a Forward P/S ratio of 0.00. This means the market is valuing SLS at $0.00 for every dollar of expected revenue over the next 12 months.